These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28130121)

  • 41. Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.
    Jaszberenyi M; Schally AV; Block NL; Zarandi M; Cai RZ; Vidaurre I; Szalontay L; Jayakumar AR; Rick FG
    Target Oncol; 2013 Dec; 8(4):281-90. PubMed ID: 23371031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
    Rekasi Z; Czompoly T; Schally AV; Boldizsar F; Varga JL; Zarandi M; Berki T; Horvath RA; Nemeth P
    Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3435-40. PubMed ID: 15728367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
    Horváth JE; Zarándi M; Groot K; Schally AV
    Endocrinology; 1995 Sep; 136(9):3849-55. PubMed ID: 7649091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).
    Kanashiro-Takeuchi RM; Takeuchi LM; Rick FG; Dulce R; Treuer AV; Florea V; Rodrigues CO; Paulino EC; Hatzistergos KE; Selem SM; Gonzalez DR; Block NL; Schally AV; Hare JM
    Proc Natl Acad Sci U S A; 2012 Jan; 109(2):559-63. PubMed ID: 22203988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The growth hormone (GH)-axis of GH receptor/binding protein gene-disrupted and metallothionein-human GH-releasing hormone transgenic mice: hypothalamic neuropeptide and pituitary receptor expression in the absence and presence of GH feedback.
    Peng XD; Park S; Gadelha MR; Coschigano KT; Kopchick JJ; Frohman LA; Kineman RD
    Endocrinology; 2001 Mar; 142(3):1117-23. PubMed ID: 11181526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine.
    Zarandi M; Csernus V; Bokser L; Bajusz S; Groot K; Schally AV
    Int J Pept Protein Res; 1990 Dec; 36(6):499-505. PubMed ID: 2090641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines.
    Barabutis N; Siejka A; Schally AV
    Int J Oncol; 2010 May; 36(5):1285-9. PubMed ID: 20372804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
    Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH (1-29)NH2.
    Kovacs M; Gulyas J; Bajusz S; Schally AV
    Life Sci; 1988; 42(1):27-35. PubMed ID: 2892105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
    Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.
    Csernus VJ; Schally AV; Kiaris H; Armatis P
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3098-103. PubMed ID: 10077643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
    Bercu BB; Yang SW; Masuda R; Walker RF
    Endocrinology; 1992 May; 130(5):2579-86. PubMed ID: 1315249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth hormone (GH)-releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels.
    Kineman RD; Kamegai J; Frohman LA
    Endocrinology; 1999 Aug; 140(8):3581-6. PubMed ID: 10433214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
    Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
    Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man.
    Aitman TJ; Rafferty B; Coy D; Lynch SS; Clayton RN
    Peptides; 1989; 10(1):1-4. PubMed ID: 2546126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.